Search Results - brain+cancer

14 Results

Sort By:

Bioreducible Poly(beta-amino ester)s for siRNA Delivery

C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown Novelty: This technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues. Value Proposition: Gene therapy is a developing medical field and there is a need for...

Published: 5/9/2024 | Inventor(s): Kristen Kozielski, Stephany Tzeng, Jordan Green

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, Disease Indication, Drug Delivery Vehicle, Glioma, Nucleic Acid, Polymers, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Genetic Alterations in Medulloblastomas - MLL Genes as Targets for Diagnosis and Therapeutics

Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found that, on average, each tumor had 11 gene alterations,...

Published: 5/9/2024 | Inventor(s): Xiaosong Zhang, Hai Yan, Gregory Riggins, Victor Velculescu, Kenneth Kinzler, Darell Bigner, Nickolas Papadopoulos, Donald Parsons, Sian Jones, Rebecca Leary, Meng Li, Bert Vogelstein

Keywords(s): Biomarker, Brain Cancer, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Medulloblastoma, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Medulloblastoma

Nanoparticle Modification of Human Adipose-derived Mesenchymal Stem Cells for Brain Cancer and Other Neurological Diseases

Human Adipose-derived Mesenchymal Stem Cells can be engineered to synthesize and release anti-tumor proteins and therefore can be used as “Trojan Horses”. The inventors have created a novel technology which encompasses a solution containing biodegradable, polymeric nanoparticles that is combined with Freshly-extracted Adipose Tissue (F.A.T.) (from...

Published: 5/9/2024 | Inventor(s): Jordan Green, Alfredo Quinones-Hinojosa

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, CNS and Neurological Disorders, Disease Indication, Drug Delivery Vehicle, Glioma, Nanoparticles, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Whole cell

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)

Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...

Published: 5/9/2024 | Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai

Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer

Acriflavine Biodegradable CCP:SA Polymers for the Treatment of Malignant Glioma

We investigated the efficacy of the intracranial delivery of a promising anti-cancer drug, whose use has not yet been described for the treatment of malignant glioma. The drug is a trypanocidal, antibacterial, antiviral agent mostly used in cases of sleeping sickness and wound healing. It has demonstrated highly effective antitumor activity against...

Published: 5/9/2024 | Inventor(s): Betty Tyler, Antonella Mangraviti, Henry Brem, Alessandro Olivi, Tula Raghavan

Keywords(s): Brain Cancer, Cancers, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Glioma, Non-novel, Polymers, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Using human neural stem cells to model brain tumors

ABSTRACTJHU researchers developed a new method to generate genetically accurate models of rare tumors, and a companion computational methodology to find therapeutic interventions that target them. They validated their human neural stem cell model of MYC-driven Group 3 medulloblastoma and showed that CDK4/6 inhibitors are active against this subgroup....

Published: 5/9/2024 | Inventor(s): Eric Raabe, Allison Hanaford, Charles Eberhart, Ulf Kahlert, Jarek Maciaczyk, Guido Nikkhah

Keywords(s): Brain Cancer, Cancers, Cell Model, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Medulloblastoma, Stem Cells

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Medulloblastoma, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools > Stem Cells, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools

SuBLIME: Automatic Brain Lesion Incidence and Detection Using Multimodality Longitudinal Magnetic Resonance Imaging

Subjects develop brain lesions over the natural course of a disease, Thus, there is a need to identify, estimate the size, and track the time course of new lesions as they are being formed and remain in the brain. Currently, this is done by a trained rteuroradiologist using sliceby- slice inspection, this process is very slow, can be prone to human...

Published: 5/9/2024 | Inventor(s): Elizabeth Sweeney, Colin Shea, Russell Shinohara, Arthur Goldsmith, Daniel Reich, Ciprian Crainiceanu

Keywords(s): Brain Cancer, Cancers, CNS and Neurological Disorders, Disease Indication, Image Display Software, Image Processing Software, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Magnetic Resonance Imaging (MRI)

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Computers, Electronics & Software, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices, Technology Classifications > Computers, Electronics & Software > Image Processing & Analysis, Clinical and Disease Specializations > Oncology > Brain Cancer

IDH1 Mutant Glioma Xenograft (JHH-273)

Invention Novelty: A stable, patient-derived IDH- 1 mutant glioma xenograft designed to evaluate potential IDH targeted drug therapies.Value Proposition: IDH-1 (Isocitrate Dehydrogenase) is a very common mutation observed in low-grade glioma tumors. Current IDH-mutated cell lines lack sufficient genetic characteristics similar to human pathologies and...

Published: 5/9/2024 | Inventor(s): Alexandra Borodovsky, Gregory Riggins

Keywords(s): Basic Research Biomarker, Brain Cancer, Cancers, Discovery/Research Tools, Disease Indication, Glioma, In Vivo Research Tool, Mouse Model, Mouse Model Xenograft

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma, Technology Classifications > Research Tools > Animal Models, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools

Self-Assembling Verteporfin Amphiphiles (SAVA) for Local Cancer Therapy

Unmet Need: Brain tumors including aggressive Glioblastoma (GBM) remain a large societal burden due to the large number of affected patients and overall poor survival rates. A promising FDA-approved drug verteporfin (VP) was identified that directly targets transcription factors upregulated in GBM, but practical use of this drug to treat GBM is limited...

Published: 5/9/2024 | Inventor(s): Sagar Shah, Juan Carlos Martinez-Gutierrez, Alejandro Ruiz-Valls, Ran Lin, Honggang Cui, Alfredo Quinones-Hinojosa

Keywords(s): Brain Cancer, Cancers, Disease Indication, Drug Delivery Vehicle, Hydrogel, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology > Brain Cancer, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Glioblastoma Biomarker for Improved Survival Prediction

TITLE: Glioblastoma Biomarker for Improved Survival PredictionCASE NUMBER: C13155UNMET NEEDGlioblastoma GBM), the most common primary brain tumor, has few available therapies providing significant improvement in survival. The median survival of patients after treatment is ~15 months, with only 3-5% surviving longer than 3 years. However, survival varies...

Published: 5/9/2024 | Inventor(s): Patrick Ha, Michael Lim, Chetan Bettegowda, Taeyoung Hwang, Chul-Kee Park, Dimitrios Mathios

Keywords(s): Biomarker, Brain Cancer, Breast Cancer, Cancers, Cervical Cancer, Clinical Diagnostics, Disease Indication, Glioma, In Vitro Diagnostics, Lung Cancer, Prognostic Biomarker

1 2